🔗 Permalink

Inventor profile of:

Daniel L. ALKON

City:

Chevy Chase, Maryland

Country:

United States

Published Applications:

40

Last publication date:

2025-02-27

Top Assignees for applications by Daniel L. ALKON

The entities that hold a legal rights for patent applications filed by inventor ALKON Daniel L.:

Synaptogenix, Inc. 14 New York, NY United States
Cognitive Research Enterprises, Inc. 7 Morgantown, WV United States
NeuroDiagnostics LLC 6 Rockville, MD United States
BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE 3 Morgantown, WV United States
WEST VIRGINIA UNIVERSITY 2 Morgantown, WV United States
Blanchette Rockefeller Neurosciences Insitute 1 Morgantown, WV United States
NEUROTROPE BIOSCIENCE, INC. 1 New York, NY United States

Recent patent applications by ALKON Daniel L.

Daniel L. ALKON from Chevy Chase, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-02-27

US20250064776A1

Human necessities

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS

#2 | 2024-12-12

US20240408056A1

Human necessities

METHODS FOR REPAIRING NERVE DAMAGE USING PKC ACTIVATING THERAPEUTIC AGENTS

#3 | 2024-10-24

US20240353429A1

DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET

#4 | 2024-06-06

US20240180869A1

Human necessities

TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORS

#5 | 2024-05-23

US20240165075A1

Human necessities

TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS

#6 | 2024-01-25

US20240025870A1

Chemistry; metallurgy

PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

#7 | 2023-04-13

US20230111650A1

Chemistry; metallurgy

Lymphocyte-Based PKCe Test for Alzheimer's Disease

#8 | 2023-01-05

US20230000943A1

Human necessities

METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF

#9 | 2022-11-10

US20220357315A1

Lymphocyte-Based Morphometric Test for Alzheimer's Disease

#10 | 2022-11-10

US20220356161A1

Chemistry; metallurgy

PKC-activating compounds for the treatment of neurodegenerative diseases

#11 | 2022-06-16

US20220184028A1

Human necessities

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS

#12 | 2022-05-19

US20220151973A1

Human necessities

Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases

#13 | 2022-05-05

US20220133687A1

Human necessities

METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS

#14 | 2022-04-28

US20220128577A1

Methods for Diagnosing Alzheimer's Disease Based on Cell Growth Rate, Size and Protein Amount

#15 | 2021-10-07

US20210308099A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

#16 | 2021-01-28

US20210023048A1

Human necessities

Dosing regimens of PKC activators

#17 | 2020-10-22

US20200331875A1

Chemistry; metallurgy

PKC-activating compounds for the treatment of neurodegenerative diseases

#18 | 2020-10-15

US20200323817A1

Human necessities

Methods for inducing synaptogenesis with synaptic growth factor activating compounds

#19 | 2019-12-05

US20190365706A1

Human necessities

Dosing regimens of PKC activators

#20 | 2019-11-21

US20190350898A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE

#21 | 2019-10-24

US20190323083A1

Chemistry; metallurgy

SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC METHODS

#22 | 2019-09-05

US20190270715A1

Chemistry; metallurgy

PKC-activating compounds for the treatment of neurodegenerative diseases

#23 | 2019-06-27

US20190192471A1

Human necessities

Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases

#24 | 2019-03-21

US20190083575A1

Human necessities

THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY

#25 | 2019-02-07

US20190041404A1

DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET

#26 | 2018-11-15

US20180325856A1

Human necessities

HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

#27 | 2018-11-01

US20180311209A1

Human necessities

DOSING REGIMENS OF PKC ACTIVATORS

#28 | 2018-10-04

US20180284103A1

Lymphocyte-based morphometric test for alzheimer's disease

#29 | 2018-10-04

US20180282784A1

Chemistry; metallurgy

LYMPHOCYTE-BASED PKCe TEST FOR ALZHEIMER'S DISEASE

#30 | 2018-09-13

US20180256537A1

Human necessities

METHODS FOR SURVIVAL AND REJUVENATION OF DERMAL FIBROBLASTS USING PKC ACTIVATORS

#31 | 2018-08-02

US20180217163A1

TREATMENT OF NEURODEGENERATIVE CONDITIONS USING PKC ACTIVATORS AFTER DETERMINING THE PRESENCE OF THE APOE4 ALLELE

#32 | 2018-02-22

US20180050016A1

Human necessities

Compositions and methods to treat niemann-pick disease

#33 | 2018-01-25

US20180024146A1

ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)

#34 | 2017-03-23

US20170079948A1

Human necessities

Compositions and methods to treat Niemann-Pick disease

#35 | 2017-01-26

US20170023552A1

CONVERGENCE OF AGGREGATION RATE WITH VALIDATED PERIPHERAL DIAGNOSTIC FOR ALZHEIMER'S DISEASE

#36 | 2016-09-08

US20160256427A1

Human necessities

Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases

#37 | 2016-03-03

US20160060236A1

Chemistry; metallurgy

PKC-activating compounds for the treatment of neurodegenerative diseases

#38 | 2016-02-25

US20160051509A1

Human necessities

Methods for Alzheimer'S disease treatment and cognitive enhancement

#39 | 2016-01-28

US20160025704A1

METHODS FOR IDENTIFYING NEUROPROTECTIVE PKC ACTIVATORS

#40 | 2014-10-30

US20140323456A1

Chemistry; metallurgy

Esters of DCPLA and methods of treatment using the same

InventorID:

1424864 ⎘